VPC-3033

VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC50: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC50=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002) [1].

Product Specifications

CAS Number

[110763-24-1]

UNSPSC

12352005

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/vpc-3033.html

Smiles

O=C1C2=C(/C(C3=C1C=CC=C3)=C\C4=CC(O)=CC=C4)C=CC=C2

Molecular Formula

C21H14O2

Molecular Weight

298.33

References & Citations

[1]Li H, et al. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer[J]. Molecular cancer therapeutics, 2013, 12 (11) : 2425-2435.